- Home
- UPXI vs TNGX Comparison
UPXI vs TNGX Comparison
Compare UPXI & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UPXI
- TNGX
- Stock Information
- Founded
- UPXI 2018
- TNGX 2014
- Country
- UPXI United States
- TNGX United States
- Employees
- UPXI N/A
- TNGX N/A
- Industry
- UPXI Medicinal Chemicals and Botanical Products
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- UPXI Health Care
- TNGX Health Care
- Exchange
- UPXI Nasdaq
- TNGX Nasdaq
- Market Cap
- UPXI 356.9M
- TNGX 351.2M
- IPO Year
- UPXI 2021
- TNGX N/A
- Fundamental
- Price
- UPXI $5.22
- TNGX $5.88
- Analyst Decision
- UPXI
- TNGX Strong Buy
- Analyst Count
- UPXI 0
- TNGX 6
- Target Price
- UPXI N/A
- TNGX $12.20
- AVG Volume (30 Days)
- UPXI 5.1M
- TNGX 2.6M
- Earning Date
- UPXI 05-16-2025
- TNGX 08-06-2025
- Dividend Yield
- UPXI N/A
- TNGX N/A
- EPS Growth
- UPXI N/A
- TNGX N/A
- EPS
- UPXI N/A
- TNGX N/A
- Revenue
- UPXI $16,562,327.00
- TNGX $40,990,000.00
- Revenue This Year
- UPXI $299.03
- TNGX N/A
- Revenue Next Year
- UPXI N/A
- TNGX N/A
- P/E Ratio
- UPXI N/A
- TNGX N/A
- Revenue Growth
- UPXI 1378.83
- TNGX 10.09
- 52 Week Low
- UPXI $1.90
- TNGX $1.03
- 52 Week High
- UPXI $22.57
- TNGX $12.02
- Technical
- Relative Strength Index (RSI)
- UPXI 46.53
- TNGX 73.28
- Support Level
- UPXI $2.73
- TNGX $5.75
- Resistance Level
- UPXI $6.57
- TNGX $6.40
- Average True Range (ATR)
- UPXI 0.66
- TNGX 0.50
- MACD
- UPXI 0.35
- TNGX -0.03
- Stochastic Oscillator
- UPXI 77.74
- TNGX 83.80
About UPXI Upexi Inc.
Upexi Inc specializes in the development, manufacturing, and distribution of consumer products. It reaches consumers through its direct-to-consumer network, wholesale partnerships, and prominent third-party platforms like Amazon.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.